Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) have been given an average rating of “Hold” by the six analysts that are presently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, two have given a hold recommendation and two have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $70.75.

Several equities research analysts have issued reports on the company. Weiss Ratings lowered Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, June 25th. Zacks Research lowered Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research note on Monday, May 18th. Canaccord Genuity Group lowered their price objective on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a report on Friday, May 15th. Finally, Oppenheimer cut shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th.

Prestige Consumer Healthcare Price Performance

Shares of PBH traded up $1.16 during trading hours on Tuesday, reaching $50.02. 161,796 shares of the company’s stock traded hands, compared to its average volume of 570,034. Prestige Consumer Healthcare has a 12 month low of $42.62 and a 12 month high of $79.58. The company has a current ratio of 3.57, a quick ratio of 2.25 and a debt-to-equity ratio of 0.54. The stock has a market cap of $2.37 billion, a PE ratio of 12.81, a price-to-earnings-growth ratio of 1.59 and a beta of 0.35. The firm’s 50 day simple moving average is $49.19 and its 200-day simple moving average is $58.16.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Wednesday, May 13th. The company reported $1.23 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.39 by ($0.16). The company had revenue of $281.62 million for the quarter, compared to the consensus estimate of $293.64 million. Prestige Consumer Healthcare had a net margin of 17.48% and a return on equity of 11.54%. The company’s revenue for the quarter was down 5.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.32 earnings per share. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. Equities analysts expect that Prestige Consumer Healthcare will post 4.45 EPS for the current year.

Insider Activity

In other news, VP Jeffrey Zerillo sold 1,207 shares of Prestige Consumer Healthcare stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $54.99, for a total value of $66,372.93. Following the transaction, the vice president owned 42,820 shares in the company, valued at approximately $2,354,671.80. The trade was a 2.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Several institutional investors and hedge funds have recently bought and sold shares of PBH. Massachusetts Financial Services Co. MA increased its holdings in Prestige Consumer Healthcare by 10.2% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 650,793 shares of the company’s stock worth $40,147,000 after buying an additional 60,496 shares in the last quarter. Nordea Investment Management AB lifted its stake in Prestige Consumer Healthcare by 547.4% during the 4th quarter. Nordea Investment Management AB now owns 615,215 shares of the company’s stock valued at $37,811,000 after acquiring an additional 520,186 shares during the period. Leeward Investments LLC MA lifted its stake in Prestige Consumer Healthcare by 23.3% during the 4th quarter. Leeward Investments LLC MA now owns 387,321 shares of the company’s stock valued at $23,894,000 after acquiring an additional 73,162 shares during the period. Legato Capital Management LLC boosted its holdings in shares of Prestige Consumer Healthcare by 532.4% during the 4th quarter. Legato Capital Management LLC now owns 27,774 shares of the company’s stock valued at $1,713,000 after acquiring an additional 23,382 shares during the last quarter. Finally, Brandes Investment Partners LP boosted its holdings in shares of Prestige Consumer Healthcare by 93.2% during the 4th quarter. Brandes Investment Partners LP now owns 606,737 shares of the company’s stock valued at $37,430,000 after acquiring an additional 292,744 shares during the last quarter. 99.95% of the stock is currently owned by institutional investors.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).